Abstract The acidic fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF) proteins are potent vascular smooth muscle cell (SMC) mitogens that are expressed by endothelial cells and SMCs in vivo. Overexpression of these proteins in transfected cell lines can result in autocrine transformation; therefore, the precise control of fibroblast growth factor gene expression in the vessel wall may be an important mechanism regulating vascular cell growth. In the present study, we demonstrate that bFGF can induce bFGF mRNA expression, but not aFGF mRNA expression, in serum-starved rat aortic SMCs. bFGF autoinduction is maximal at 4 hours, requires de novo RNA and protein synthesis, and is mediated predominantly by a protein kinase C-dependent signaling pathway. Furthermore, aFGF treatment of rat SMCs also increases bFGF mRNA and protein expression; however, aFGF mRNA levels are only slightly modulated. These results suggest that the local release of aFGF or bFGF within the vessel wall could promote a prolonged period of elevated bFGF synthesis. This, in turn, could be of importance in the SMC hyperplasia that occurs in response to vascular injury and during atherosclerotic plaque formation. (Circ Res. 1994;75:261-267.) Key Words * fibroblast growth factor * smooth muscle cells * gene expression * protein kinase C A cidic fibroblast growth factor (aFGF) are also expressed by vascular SMCs in vivo14-16; however, these cells are essentially quiescent.17-9 This implies that the level of FGF gene expression and/or FGF accessibility to cell surface receptors determines whether these mitogens are biologically active in vivo. In support of the first possibility, cDNA transfection experiments indicate a strong correlation between acquisition of a transformed phenotype and high levels of aFGF6'20'21 or bFGF22-25 expression. In support of the second possibility, Lindner and Reidy26 reported that the administration of a bFGF-specific antibody before balloon catheterization of the rat carotid artery significantly inhibited injury-induced medial SMC proliferation. It is likely that the antibody was neutralizing bFGF released from dead or injured cells and destined for FGF receptors on neighboring SMCs. However, this may not be the sole mechanism for FGF release in vivo; recent studies by Mignatti and colleagues27'28 indicate that bFGF can exit viable cells by a mechanism independent of the classic endoplasmic reticulum-Golgi complex secretory pathway.
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The degree of aFGF mRNA expression varied somewhat during the duration of the experiment but was not significantly increased above baseline levels by bFGF treatment (Fig 1B) . SMCs were serum-starved and then treated for 4 hours with increasing concentrations of bFGF to determine whether bFGF autoinduction was a dose-dependent phenomenon. Elevated bFGF mRNA expression was apparent over the entire 300-fold range of bFGF concentrations, with maximal induction (approximately ninefold) detected at a final protein concentration of 10 ng/mL or z560 pmol/L (Fig 3) . We next investigated whether de novo protein synthesis was required for bFGF autoinduction. Serumstarved SMCs were treated with bFGF for 4 hours in the absence or presence of cycloheximide, an inhibitor of translation elongation. RNA was prepared, and bFGF mRNA levels were examined by RNA gel blot hybridization. Cycloheximide treatment did not alter the basal level of bFGF mRNA expression but completely suppressed bFGF autoinduction ( Fig 4A) ; thus, autoinduction requires the synthesis of intermediary proteins and therefore can be classified as a delayedearly cellular response.
The increase in bFGF mRNA levels observed after bEGF addition could be due to enhanced gene transcription and/or increased transcript stability. It is likely that this response is due, at least in part, to transcriptional activation of the bFGF gene, since bFGE autoinduction did not occur in the presence of actinomycin D, an RNA synthesis inhibitor (Fig 4B) (Fig 6A) . A slight increase above baseline levels was detected at one time point, 12 hours. In contrast, aFGF significantly increased the level of bFGF mRNA expression, with kinetics similar to those observed after bFGF treatment (Fig 6B) . Specifically, increased bFGF mRNA levels were evident at 2 hours after aFGF FIG 6 . Expression of acidic fibroblast growth factor (aFGF) and basic fibroblast growth factor (bFGF) mRNA in aFGF-treated rat smooth muscle cells (SMCs). A, Serum-starved SMCs were either left untreated or treated with aFGF for the indicated time periods. RNA was prepared, and equivalent amounts of each sample were analyzed by RNA gel blot hybridization using aFGF (top) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH, bottom) cDNA probes. B, The same RNA samples were also analyzed by RNA gel blot hybridization using bFGF (top) or GAPDH (bottom) cDNA probes.
addition, and peak expression was at 4 hours. Densitometric analyses of aFGF and bFGF transcript expression (normalized with respect to GAPDH mRNA signal intensity) are presented in Fig 7. The RNA gel blot hybridization results described so far were all obtained when using the same rat SMC line cultured to relatively late passage levels (15 through 25). We felt that it was important to test whether the aFGF and bFGF genes were also differentially regulated by aFGF or bFGE in (1) another SMC isolate and (2) low-passage-number SMCs. Therefore, another line of SMCs was obtained and cultured to passage 7. Serumstarved cells were treated with aFGF or bFGF for 4 hours. RNA was prepared, and aFGF and bFGF mRNA levels were assayed by RNA gel blot hybridization. Neither growth factor significantly altered the degree of aFGF mRNA expression (data not shown); in contrast, both polypeptides increased bEGF mRNA expression (Fig 8) . Consistent with the studies described above using late passage cells, bovine brain-derived aFGF was a more potent inducer (-8-fold increase) than an equivalent amount of recombinant human bFGF (z=-5.3-fold increase). Finally, we used Western blot analysis to investigate whether FGF treatment of SMCs resulted in elevated bFGF production. Serum-starved SMCs (late passage) were either left untreated or treated with aFGF for different lengths of time. We used aFGF instead of bFGF for these experiments, since exogenously supplied protein would likely be sequestered in extracellular matrix and consequently present in the SMC extracts. Cells were harvested by scraping in an SDSbased solution (which will lyse nuclei and extract extracellular matrix), and equivalent amounts of protein were analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotting with rabbit anti-bFGF IgG. This antibody reagent does not recognize aFGF, the FGF family member most similar to bFGF in amino acid sequence (Fig 9A) . Four major species of bFGF with molecular masses of ::=17, 20, 21, and 26 kD were expressed in rat SMCs. These immunoreactive proteins were not detected when either control rabbit IgG or anti-bFGF IgG preincubated with recombinant bFGF was used as the primary antibody reagent (Fig 9A) . The expression level of all four bFGF species increased with similar kinetics after aFGF treatment; as estimated by densitometry, peak expression (approximately twofold induction) occurred at 12 hours (Fig 9B) .
Discussion
The results presented here demonstrate that aFGF or bFGF stimulation of serum-starved rat SMCs induces bFGF mRNA and protein expression. The 
